Clinical trials on semaglutide have studied participants for more than two years, and similar medicines have been used safely for up to a decade
"If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally -- removing barriers and redefining how obesity is treated around the world," Kenneth Custer, Eli Lilly's executive vice president and president of Lilly Cardiometabolic Health, said in a statement
The underlying pathogenesis seems to be related to an inflammatory response to foreign microcapsules due to a potential deficiency of enzymes needed to break down the poly-(d,l-lactide- co -glycolide) material into lactic and glycolic acid [58,59,60]
Those two facts fit together, although it is still worth remembering that better average performance in trials does not guarantee that every patient will respond better to tirzepatide individually
Researchers also need to understand who benefits, who stops treatment because of side effects, what happens after interruption, and whether longer-term risks remain acceptable
